Enliven Therapeutics (ELVN) News Today $20.13 -0.38 (-1.85%) As of 11:16 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stake Decreased by Ally Bridge Group NY LLCAlly Bridge Group NY LLC cut its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 39.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 141,710 shares of the company's stock after sMay 4 at 7:45 AM | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by 5AM Venture Management LLC5AM Venture Management LLC lowered its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 7.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,629,765 shares of the company's stock after selling 122,409 shares during tMay 4 at 7:22 AM | marketbeat.comAcuta Capital Partners LLC Decreases Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Acuta Capital Partners LLC lowered its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 9.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 267,368 shares of the company's stock after selling 29,00May 4 at 7:11 AM | marketbeat.comBoxer Capital Management LLC Acquires New Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Boxer Capital Management LLC bought a new position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 671,358 shares of the company's stoMay 4 at 6:25 AM | marketbeat.comRA Capital Management L.P. Sells 212,247 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)RA Capital Management L.P. reduced its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 20.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 848,986 shares of the company's stock afteMay 3 at 7:49 AM | marketbeat.comMarshall Wace LLP Sells 96,624 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)Marshall Wace LLP reduced its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 70.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 41,382 shares of the company's stock after selling 96,6May 3 at 3:47 AM | marketbeat.comBenjamin Hohl Sells 3,250 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockMay 1, 2025 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by Boothbay Fund Management LLCBoothbay Fund Management LLC lowered its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 21.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 104,890 shares of the company's stock after selliApril 30, 2025 | marketbeat.comLord Abbett & CO. LLC Raises Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Lord Abbett & CO. LLC lifted its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 20.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 386,211 shares of the company's stock after purchasiApril 30, 2025 | marketbeat.comArtia Global Partners LP Makes New Investment in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Artia Global Partners LP acquired a new stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 102,900 shares of the companyApril 29, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. reduced its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 18.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 650,000 shares of the compaApril 29, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Trading 10.8% Higher - Should You Buy?Enliven Therapeutics (NASDAQ:ELVN) Trading 10.8% Higher - Here's What HappenedApril 24, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells $80,350.00 in StockApril 24, 2025 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 5,000 SharesEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 5,000 shares of the firm's stock in a transaction dated Thursday, April 17th. The shares were sold at an average price of $16.42, for a total transaction of $82,100.00. Following the completion of the sale, the chief executive officer now owns 985,392 shares in the company, valued at $16,180,136.64. This represents a 0.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.April 23, 2025 | marketbeat.comEnliven Therapeutics: Awaiting Additional Trial DataApril 22, 2025 | seekingalpha.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells 5,000 Shares of StockApril 22, 2025 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Purchased by Fmr LLCFmr LLC raised its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 3.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,495,871 shares of the company's stock after acquiring an additional 199,692 shApril 15, 2025 | marketbeat.comFederated Hermes Inc. Takes $2.65 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Federated Hermes Inc. acquired a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 117,552 shares of the company's stock, valuApril 15, 2025 | marketbeat.comVanguard Group Inc. Purchases 55,283 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)Vanguard Group Inc. raised its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 2.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,975,655 shares of the coApril 14, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Sets New 52-Week Low - Time to Sell?Enliven Therapeutics (NASDAQ:ELVN) Hits New 1-Year Low - Should You Sell?April 11, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Shares Down 9.1% - Here's What HappenedEnliven Therapeutics (NASDAQ:ELVN) Shares Down 9.1% - What's Next?April 10, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 6,667 SharesApril 10, 2025 | insidertrades.comEnliven Therapeutics (NASDAQ:ELVN) Sees Large Volume Increase - Should You Buy?Enliven Therapeutics (NASDAQ:ELVN) Sees Unusually-High Trading Volume - Should You Buy?April 4, 2025 | marketbeat.comEnliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual MeetingApril 2, 2025 | prnewswire.comEnliven Therapeutics (NASDAQ:ELVN) Stock Price Down 4.9% Following Insider SellingEnliven Therapeutics (NASDAQ:ELVN) Shares Down 4.9% Following Insider SellingApril 2, 2025 | marketbeat.comPictet Asset Management Holding SA Has $21.88 Million Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Pictet Asset Management Holding SA boosted its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 16.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 972,293 shares of the company's stock afterApril 2, 2025 | marketbeat.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 3,250 Shares of StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 3,250 shares of the firm's stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $21.33, for a total value of $69,322.50. Following the sale, the chief financial officer now directly owns 23,000 shares of the company's stock, valued at $490,590. This represents a 12.38 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.April 1, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $22,500.00 in StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 1,000 shares of the company's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $22.50, for a total value of $22,500.00. Following the completion of the sale, the chief financial officer now directly owns 23,000 shares in the company, valued at approximately $517,500. The trade was a 4.17 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.March 27, 2025 | marketbeat.comBenjamin Hohl Sells 1,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockMarch 27, 2025 | insidertrades.comEnliven Therapeutics (NASDAQ:ELVN) Trading Down 7.8% - Here's What HappenedEnliven Therapeutics (NASDAQ:ELVN) Trading Down 7.8% - Should You Sell?March 26, 2025 | marketbeat.com16,322 Shares in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Purchased by Intech Investment Management LLCIntech Investment Management LLC purchased a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 16,322 shares of the company's stock, valued at approximaMarch 26, 2025 | marketbeat.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells 12,500 Shares of StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph P. Lyssikatos sold 12,500 shares of the firm's stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $20.61, for a total value of $257,625.00. Following the sale, the insider now directly owns 1,002,688 shares of the company's stock, valued at approximately $20,665,399.68. This represents a 1.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.March 22, 2025 | marketbeat.comHC Wainwright Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock PriceHC Wainwright upped their target price on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a "buy" rating in a research note on Friday.March 22, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells $257,625.00 in StockMarch 22, 2025 | insidertrades.comSamuel Kintz Sells 12,500 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 12,500 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $20.83, for a total transaction of $260,375.00. Following the completion of the transaction, the chief executive officer now owns 990,392 shares in the company, valued at $20,629,865.36. The trade was a 1.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.March 20, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $260,375.00 in StockMarch 20, 2025 | insidertrades.comLifesci Capital Issues Optimistic Forecast for ELVN EarningsEnliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - Equities researchers at Lifesci Capital raised their FY2025 earnings estimates for shares of Enliven Therapeutics in a research report issued to clients and investors on Monday, March 17th. Lifesci Capital analyst S. Slutsky now anticipatesMarch 20, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPSEnliven Therapeutics (NASDAQ:ELVN - Get Free Report) announced its earnings results on Thursday. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.07.March 14, 2025 | marketbeat.comEnliven Therapeutics, Inc.: Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business UpdateMarch 14, 2025 | finanznachrichten.deTD Cowen Reaffirms Their Buy Rating on Enliven Therapeutics (ELVN)March 14, 2025 | markets.businessinsider.comEnliven Therapeutics Reports 2024 Financial ResultsMarch 14, 2025 | tipranks.comEnliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business UpdateMarch 13, 2025 | prnewswire.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $142,940.48 in StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 6,667 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $21.44, for a total value of $142,940.48. Following the completion of the transaction, the chief operating officer now directly owns 323,310 shares in the company, valued at $6,931,766.40. This trade represents a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.March 12, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Stock Price Up 4.5% - Should You Buy?Enliven Therapeutics (NASDAQ:ELVN) Trading 4.5% Higher - Here's WhyMarch 7, 2025 | marketbeat.comEnliven Therapeutics (ELVN) Projected to Post Quarterly Earnings on ThursdayEnliven Therapeutics (NASDAQ:ELVN) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports.March 6, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $66,332.50 in StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $20.41, for a total transaction of $66,332.50. Following the transaction, the chief financial officer now directly owns 13,000 shares in the company, valued at approximately $265,330. This represents a 20.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.March 4, 2025 | marketbeat.comEnliven Therapeutics to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | prnewswire.comEnliven Therapeutics (NASDAQ:ELVN) Shares Gap Down - Here's What HappenedEnliven Therapeutics (NASDAQ:ELVN) Shares Gap Down - Here's WhyFebruary 13, 2025 | marketbeat.comEnliven Therapeutics COO Anish Patel sells $146,205 in stockFebruary 11, 2025 | msn.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $146,207.31 in StockFebruary 11, 2025 | insidertrades.com Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address ELVN Media Mentions By Week ELVN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELVN News Sentiment▼1.250.73▲Average Medical News Sentiment ELVN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELVN Articles This Week▼123▲ELVN Articles Average Week Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Akero Therapeutics News Today Merus News Today MorphoSys News Today Scholar Rock News Today Protagonist Therapeutics News Today Crinetics Pharmaceuticals News Today SpringWorks Therapeutics News Today Organon & Co. News Today Catalyst Pharmaceuticals News Today Viking Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELVN) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ELVN Stock Free ELVN Stock Alerts